SCHEMBL1287644

SCHEMBL1287644

CCCCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TTR P02766 4/20 1.00
EYA3 Q99504 7/20 0.78
CYP2C19 P33261 4/20 0.78
CYP2C9 P11712 3/20 0.78
THRB P10828 3/20 0.78
SLC22A12 Q96S37 3/20 0.78
PTPN1 P18031 2/20 0.78
MEN1 O00255 2/20 0.78
ABCB11 O95342 2/20 0.78
LMNA P02545 2/20 0.78
PGR P06401 2/20 0.78
ADRA2A P08913 2/20 0.78
TBXA2R P21731 2/20 0.78
OPRM1 P35372 2/20 0.78
SLC6A3 Q01959 2/20 0.78
KMT2A Q03164 2/20 0.78
EYA2 O00167 1/20 0.78
ABCC4 O15439 1/20 0.78
PLIN1 O60240 1/20 0.78
NR1I2 O75469 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11844336 0.88 TTR (0.79) TTREYA3CYP2C19CYP2C9THRB
Benzbromarone SCHEMBL19205474 0.88 SLC22A12 (1.00) TTREYA3CYP2C19CYP2C9THRB
Benzbromarone SCHEMBL48993 0.88 SLC22A12 (1.00) TTREYA3CYP2C19CYP2C9THRB
Benzbromarone SCHEMBL29361528 0.88 SLC22A12 (1.00) TTREYA3CYP2C19CYP2C9THRB
SCHEMBL25392883 0.87 TTR (0.77) TTREYA3CYP2C19CYP2C9THRB
SCHEMBL11847986 0.87 EYA3 (0.78) TTREYA3CYP2C19CYP2C9THRB
SCHEMBL6335384 0.87 EYA3 (1.00) TTREYA3CYP2C9THRBPTPN1
Benzbromarone SCHEMBL6761161 0.87 SLC22A12 (0.93) TTREYA3CYP2C19CYP2C9THRB
SCHEMBL6336482 0.86 TTR (0.76) TTREYA3CYP2C19CYP2C9THRB
SCHEMBL11843232 0.86 EYA3 (0.77) TTREYA3CYP2C19CYP2C9THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023149549-A1 NOVEL PHARMACEUTICAL COMPOSITION 国立大学法人富山大学 2023-08-10 WO disclosed
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action J-PHARMA CO., LTD. (JP) 2018-06-26 US disclosed
US-20130225673-A1 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION J-PHARMA CO., LTD. (JP) 2013-08-29 US disclosed
WO-2012048058-A2 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION J-PHARMA CO., LTD. (JP) 2012-04-12 WO disclosed
US-6844358-B2 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2005-01-18 US disclosed
US-20040102480-A1 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH (US) 2004-05-27 US disclosed
US-6509360-B1 a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia. WYETH 2003-01-21 US disclosed
EP-1077965-A1 PHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
US-6166069-A Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION (US) 2000-12-26 US disclosed
WO-1999058519-A1 PHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed
US-4400387-A USEFUL IN VETERINARY MEDICINE FOR TREATMENT OF PSYCHOLOGICAL DISORDERS S. A. LABAZ-SANOFI N.V. (FR) 1983-08-23 US disclosed
US-3975537-A SUBSTITUTED BENZOFURANS SMITH KLINE (US) 1976-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10005750-B2 Developing potent urate transporter inhibitors: compounds designed for their uricosuric action SLCO2B1, SLCO2A1, SLC10A6 TTR 1944/4885EYA3 4828/4885CYP2C19 269/4885
US-20130225673-A1 DEVELOPING POTENT URATE TRANSPORTER INHIBITORS: COMPOUNDS DESIGNED FOR THEIR URICOSURIC ACTION SLCO2B1, SLCO2A1, SLC10A6 TTR 1944/4885EYA3 4828/4885CYP2C19 269/4885
US-20040102480-A1 Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, GCKR TTR 1292/4885EYA3 4109/4885CYP2C19 906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.